about
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C TherapyThe association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.Treatment of patients with HCV related cirrhosis: many rewards with very few risks.Safety of direct antiviral agents in real life.De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir.Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease.Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis.Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression.Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: The interferon-inducible gene IFI16Proteomics to Predict Hepatitis C Therapy Outcome: Where Do We Stand?High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter studyProcoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosisComparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort
P50
Q26795750-38C158F5-A744-45A5-A6C7-0FAB6B3BB833Q33755525-93D51D8B-4EF0-489F-9E4A-F5F4263F8951Q34110246-65F30969-0FD2-4D60-AAE2-DAB13B09CB63Q35156156-B208D56A-154F-4047-B6D7-08A2B9F84A2BQ35787526-6A81DEA1-2F11-43B6-83A3-FD6717271FCCQ36052963-521CE162-A0ED-4FE7-B152-2A1D9E25FDF4Q36142732-9368C447-E1E5-4BCF-862D-62D31EB3225FQ38148912-E7291D68-3DED-4445-8F36-B5EEECD83957Q38169598-40D614E8-6573-463A-AFA1-4531FB601E9CQ38189959-D6513BEF-5013-46E7-912E-90C217806C4CQ38341993-AE9C25BF-B972-427D-BB61-662915A102F8Q38758591-4D102A4F-765D-41A1-B377-444281EEAA17Q39526702-03AADBB3-0C59-495C-A1B5-51CBEA7840AFQ40155391-4DA9F1DB-5AFC-4B1B-BE97-1585B0366E24Q40616904-A8F68454-4838-4647-87E3-500D5F2C7DA0Q40741855-94A1503E-44BD-46AA-A558-A5DFB7FC47E5Q40753034-269F79B7-EB68-441B-849B-8F23A7645F37Q41372756-5DAE820F-6AE7-434D-B26A-27446CFAB00FQ41680874-A9A45B71-D727-438E-9131-65B6690D9DA6Q42156382-36F7F721-D6CA-467B-8B86-34FE3B73ECF6Q42271855-0BDB4B66-9934-4CD7-861D-F063C447F14CQ42980606-0041CEF1-041A-4CDD-B165-9ADA5417C37CQ42991111-334C948D-C2DC-4414-AB12-095417AE3D09Q42998773-D25B1B52-3899-4D62-9E4F-CF1BD94CAA75Q43039467-68EA0D8A-7FF0-4004-B45F-299E28A09C83Q43040683-9F4995AA-F3C8-438E-9E86-2B9ABCB43925Q45354091-7C1EE3E4-F6DF-4A63-B790-3C4660AC8B0AQ45360205-CDE87A35-9323-4587-8A08-E3DD3D51048DQ49607585-949A2310-C4CB-45B8-8532-D5BE93E32C60Q50275817-A0D050BC-DC70-47CF-BE37-659CD11980DEQ62488665-A3C19774-9A07-43D6-998B-50A81EB3DFEBQ63405897-345D7CFC-14DB-4E9E-8FD7-A2F0D65B01DEQ92247495-FDBE04A5-7EB3-49AD-9732-534AD6CD0FDEQ92661618-841B64E4-597A-431C-BDA1-486B75C58E1BQ95592483-99B4EC03-80A1-4E80-AEB5-222F964FD327
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Roberta D'Ambrosio
@ast
Roberta D'Ambrosio
@en
Roberta D'Ambrosio
@es
Roberta D'Ambrosio
@nl
Roberta D'Ambrosio
@sl
type
label
Roberta D'Ambrosio
@ast
Roberta D'Ambrosio
@en
Roberta D'Ambrosio
@es
Roberta D'Ambrosio
@nl
Roberta D'Ambrosio
@sl
prefLabel
Roberta D'Ambrosio
@ast
Roberta D'Ambrosio
@en
Roberta D'Ambrosio
@es
Roberta D'Ambrosio
@nl
Roberta D'Ambrosio
@sl
P1053
K-3078-2016
P106
P1153
12779743800
P21
P31
P3829
P496
0000-0003-0019-1153